Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.81 |
| ▸ | PTGER3 | P43115 | 10/20 | 0.81 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17534451 | 1.00 | PTGER4 (0.81) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL17534447 | 1.00 | PTGER4 (0.81) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL17534449 | 1.00 | PTGER4 (0.81) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL19466666 | 1.00 | PTGER4 (0.81) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL17534508 | 1.00 | PTGER4 (0.81) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL17534740 | 1.00 | PTGER4 (0.81) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL17534536 | 1.00 | PTGER4 (0.81) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL19466661 | 1.00 | PTGER4 (0.81) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL17534688 | 1.00 | PTGER4 (0.81) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL17534444 | 1.00 | PTGER4 (0.81) | PTGER4PTGER3PTGER2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3235817-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-10-25 | — | — | EP | claimed |
| US-9688627-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-27 | — | — | US | claimed |
| EP-2989098-B1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2017-05-10 | — | — | EP | claimed |
| US-20160060216-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2016-03-03 | — | — | US | claimed |
| EP-3235817-B1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-3235817-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9688627-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-2989098-B1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160158413-A1 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158413-A1 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160060216-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060216-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER3 3/4885PTGER2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.